<DOC>
	<DOC>NCT00423813</DOC>
	<brief_summary>The objective of this trial is to evaluate the safety and efficacy of Xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.</brief_title>
	<detailed_description>The trial is a randomized, double blind, placebo controlled, parallel group trial in subjects diagnosed with fibromyalgia in accordance with the American College of Rheumatology. Total duration is up to twenty-two (22) weeks of trial participation. Subjects will undergo a screening and withdrawal/washout period lasting up to five (5) weeks combined followed by baseline period lasting one (1) week. Total treatment duration will be fourteen (14) weeks followed by a two week safety follow-up post treatment period. During the screening and withdrawal/washout period, no study medication will be given; however rescue medication up to 4 grams per day of acetaminophen (paracetemol) will be allowed.</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Male or female subjects, 18 years or older who meet the American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia. Subjects will be excluded if they have a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms. Any other condition that will cause a risk to subjects if they participate in the trial is also a reason for exclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>FMS</keyword>
	<keyword>Fibro</keyword>
	<keyword>pain</keyword>
	<keyword>Body pain</keyword>
	<keyword>tenderness</keyword>
	<keyword>stiffness</keyword>
	<keyword>muscular pain</keyword>
	<keyword>joint pain</keyword>
</DOC>